부산대학교 도서관

At Jikei University Hospital, 18 living-donor liver transplantations (LDLT) were performed from February 2007 to June 2016. Of these, 10 recipients received LDLT for end-stage liver disease (ESLD) due to primary biliary cholangitis (PBC), and details were as follows; median age of 49 years, female in 9 and two ABO-incompatible transplant. Median postoperative hospital stay of donors and recipients were 10 and 29.5 days, respectively. All donors and recipients made satisfactory recovery, and remain well with a median follow-up of 3.2-year. Initial immuno-suppressants were tacrolimus and steroids, which were switched to cyclosporine A and steroids between 3 and 13 months after LDLT to prevent PBC recurrence. Three patients received liver biopsy after LDLT due to acute cellular rejection, and no histological findings of PBC recurrence were identified in all 3 patients. In conclusion, our treatment strategy for ESLD due to PBC seems to be safe and acceptable.